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ABSTRACT
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across human skin, as compared to the basic opioid antagonist

or opioid agonist.

US. Cl.
USPC ................ .. 546/44; 546/45; 546/46; 514/282

13 Claims, 14 Drawing Sheets

US. Patent

Feb. 18, 2014

Sheet 1 0f 14

US 8,653,271 B2

FIGURE 1
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FIGURE 2
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Figure 3.
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3Reagents and conditions: (a) CHzClg or THF, Base = TEA or Pyridine, t = 0 °C, Argon.
(b) CHgClg, TEA, t = 0 °C, Argon, Naltrexone. (c) CHgClg, TEA, t = 0 °C, Argon, Naltrexol.
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Figure 4.
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a‘Reagents and conditions: (a) NaOH, formamidinesul?nic acid, 80-85°C, 1.5 h. (b) COC12,
CHZCIZ, TEA, t = 0 °C, Argon.
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Figure 5

(a) COC12, CHZCIZ, TEA, t I 0 oc, Argon. (b) NTX, CH2C12,TEA, t z 0 oc, Argon. (c)
NTXOL, CHZCIZ, TEA, t = 0 cc, Argon.
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Figure 6
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3 A schematic diagram showing stepwise hydrolytic cleavage of the carbonate codrug 25,
into NTX and BUOH in isotonic phosphate buffer, pH 7.4 at 32°C.
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FIGURE 7
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FIGURE 8
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FIGURE 9
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FIGURE 10
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FIGURE 1 1
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FIGURE 12

NTXOL

(control)
BUPOH from

“CB-NTXOL
E BUPOH
o

NTXOL from
CB-NTXOL
BUPOH

CB-NTXOL
BUPOH
0

0.5

1

1.5

2

pmol NTXOL equivalent/g of skin

2.5

US. Patent

Feb. 18, 2014

Sheet 14 0114

US 8,653,271 B2

FIGURE 14
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ENHANCING TRANSDERMAL DELIVERY
OF OPIOID ANTAGONISTS AND AGONISTS
USING CODRUGS LINKED TO BUPROPION
OR HYDROXYBUPROPION

chemical and pharmacokinetic properties of the codrug are
superior to those of the individual parent drugs. Thus, careful
design of the codrug entity can afford a unique product that

may have superior physicochemical properties for drug deliv
ery, compared to those of the individual drug entities them

selves, leading to improved pharmaceutical properties. In

CROSS REFERENCE TO RELATED
APPLICATIONS

addition, there are also other factors, such as the ability to

control drug delivery by appropriate design of the biolabile
linker(s) connecting the tWo drug entities, and the effect that

This application claims priority under 35 USC §119 to
US. Provisional Application No. 60/853,761 ?led Oct. 24,
2006 and US. Provisional Application No. 60/852,394 ?led
Oct. 18, 2006, the disclosures of Which are incorporated
herein by reference.

simultaneous delivery of the tWo drugs, as one chemical

entity, Will have on the pharrnacokinetics of each respective
drug. Because the skin and plasma have an abundance of

esterase enZymes, codrugs With esterase-susceptible linkages
can be cleaved by these enZymes to release the active parent

drugs in tissue and plasma.

GOVERNMENT INTERESTS

A codrug or a mutual prodrug consists of tWo drugs chemi

cally linked together in order to improve the drug delivery

A portion of this invention Was made With US. Govem
ment support under a grant from the National Institutes of
Health under NIH Grant R0lAA0l3853. The Government

may have certain rights in this invention.

properties of one or both drugs. This unique concept of a
codrug has been utiliZed to improve ocular delivery of an
20

antiglaucoma agent, ethacrynic acid (CynkoWska et al.,
Bioorganic & Medicinal Chemistry Letters 15 (2005) 3524
3527). Other examples of codrugs include facilitated gas
trointestinal absorption of loW molecular Weight heparin
(LMWH) via conjugation to deoxycholic acid (DOCA) to

FIELD OF THE INVENTION

This invention relates to novel codrugs, and more particu

larly to novel codrugs comprising bupropion or hydroxybu
propion and an opioid antagonist or an opioid agonist joined
together by chemical bonding. The codrugs possess increased
bioavailability as compared to the parent drugs.

25

BACKGROUND OF THE INVENTION

30

form LMWH-DOCA (Lee et al., J. Control. Release 111

(2006) 290-298) and dual-acting thromboxane antagonist
synthase inhibitors (BroWn et al., Bioorganic & Medicinal
Chemistry Letters 6 (1996) 273-278).
Opioid agonists are useful for treatment of a number of

conditions, including chronic pain, acute pain and depres
sion. Opioid antagonists are useful for treatment of alcohol

dependence, opioid addiction, and smoking. Naltrexone

Transdermal delivery is desirable to reduce the side effects
associated With the oral administration of drugs. Such side
effects can include abdominal pain, nausea and vomiting.

Further, transdermal delivery offers a patient freedom from

35

injections and surgical implantations. Transdermal delivery
also bypasses the signi?cant metabolism associated With oral

administration of drugs. Transdermal delivery is generally
provided through a transdermal patch Which provides sus
tained release of a drug.

40

FolloWing its application to the skin, the therapeutic e?i
ability to penetrate the skin fast enough to provide the plasma
concentrations required to elicit the desired pharmacological
45

once VIVITROLTM is injected, it cannot be easily discontin
ued Without painful surgical removal. There is a need for

etration across the skin. Skin permeability can be increased
50

via electroporation or iontophoresis, ultrasonic enhancers,
and a variety of other approaches. Although these enhance

release, reduced side effects, and the ability to readily discon

tinue therapy.
55

activity of BUP might be due to, or receive substantial con

tributions from its major active human metabolite, hydroxy
60

HoWever; there are potential advantages in delivering the
advantage is that often, When the tWo drugs are chemically

linked together in the codrug structure, the resulting physico

bupropion (BUPOH) (Schroeder, J Clin Psychiatry 44 (1983)
79-81 and Belson and Kelley, J Emerg Med 23 (2002) 223
30). Both BUP and BUPOH have excellent physicochemical
properties that alloW for transdermal delivery, and chemical

directly or by means of a cleavable, biolabile covalent linker.
Many diseases are treated by a combination of therapeutic
agents that are co-administered in separate dosage forms.

co-administered agents as a single chemical entity. One

Bupropion (BUP) is an aminoketone used as an antidepres
sant and non-nicotine aid to smoking cessation (Johnston et

al., Nicotine Tob Res 3 (2001) 131-40). The pharmacological

able drugs is the codrug approach.
A codrug comprises tWo different drugs Within a single
chemical entity. The tWo drugs may be connected either

methods for transdermally transporting a therapeutically
effective amount of opioid antagonists and agonists, such as
Naltrexone, in order to provide bene?ts such as controlled

ment technologies are still under active investigation, deliv
er‘ing macromolecules into the skin remains a signi?cant

challenge. See, e.g., Park et al., J. Control. Release 104 (2005)
51-66 and Martanto et al., Pharrn. Res. 21 (2004). One ofthe
strategies used to enhance skin permeation of poorly perme

2229-2233, NeW Jersey). In addition, although long-lasting
Naltrexone depot formulations have shoWn plasma levels for
up to 30 days (GalloWay et al., BMC Psychiatry 5 (2005) 18),

transdermal drug delivery is providing su?icient drug pen
through the use of chemical enhancers, electrical enhancers

REVIA®, an FDA approved 50 mg tablet of Naltrexone

Hydrochloride, and as VIVITROLTM, the recently FDA
approved 28-day controlled release 380 mg depot form of
Naltrexone. HoWever, REVIA® is poorly bioavailable, With
documented side effects (PDR, Medical Economics, 1996,

cacy of a drug for transdermal delivery mainly depends on its
activity. A large majority of drugs are unable to cross the skin
at therapeutic rates due to the barrier imposed by the skin’s
outer stratum corneum layer. Thus, the main challenge in

(NTX), for example, is an opioid antagonist used in the treat
ment of opiate addiction and alcohol dependence (Volpicelli
et al., Arch Gen Psychiatry 49 (1992) 876-80 and Wand et al.,
Alcohol Clin Exp Res 24 (2000) 1385-91). 6-[3-naltrexol
(NTXOL) is the active metabolite of NIX (Volpicelli, Lancet
346 (1995) 456 and Verebey et al., Clin Pharmacol Ther 20
(1976) 315-28). Naltrexone is currently available as

linkage to BUP or BUPOH should improve the skin perme
65

ability characteristics of opioid antagonists and agonists.
The present invention is directed to novel codrugs com

prising bupropion or hydroxybupropion and an opioid

US 8,653,271 B2
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antagonist or an opioid agonist joined together by chemical
bonding. The codrugs provide a signi?cant increase in the

naltrexol (control, n:5). The dotted line (----) indicates the
plasma concentration after the removal of the formulation.

transdermal ?ux across human skin, as compared to the basic

opioid antagonist or opioid agonist. Preferably, the opioid

DESCRIPTION OF THE INVENTION

antagonist is NTX or NTXOL. The codrug of the present
invention may increase the transdermal drug delivery rate
either by a solubility improvement or by a permeability

or BUPOH and an opioid antagonist or an opioid agonist

improvement, or a combination of both.

joined together by chemical bonding. According to the

The present invention relates to codrugs comprising BUP

present invention, it has been discovered that the novel
codrugs of the invention provide a signi?cant increase in the

SUMMARY OF THE INVENTION

transdermal ?ux of the codrugs across human skin, as com

pared to the basic opioid antagonists and agonists.

In one aspect, the present invention provides a novel

codrug, Which improves the oral bioavailability of the com
ponent drugs. The term “codrug” as used in the speci?cation
and claims means tWo different drugs joined together by
chemical bonding. In the codrug of the present invention, one
of the drugs is BUP or BUPOH. The other drug is an opioid
antagonist or an opioid agonist. The drugs must have one or
more connecting bonds or groups. On introduction of the

Preferably, the codrug comprises one molecule of BUP or
BUPOH and one molecule of an opioid antagonist or an

opioid agonist j oined together by chemical bonding. BUPOH
is preferred.
Suitable opioid agonists and antagonists include Naltrex

one, Buprenorphine, Butorphanol, Codeine, Dihydroco
20

codrug into the body, the chemical bond is disrupted and the
drugs become available for their intended purposes.

phine, Naloxone, 6-[3-Naltrexol, PhenaZocine, Pholcodine, or
6-0t-Naltrexol. Preferred opioid antagonists are Naltrexone

The present invention further provides for a method for

delivery of the codrug components by biotransforming the
codrug into tWo active drug molecules by hydrolysis or enZy

deine, Dihydromorphine, Ethymorphine, Hydromorphone,
Levallorphan, Levorphanol, Nalbuphine, Nalmefene, Nalor
and 6-[3-Naltrexol. 6-[3-Naltrexol is particularly preferred.

25

The codrug comprises one or more connecting bonds or

matic digestion. The term “biotransforming” as used herein

groups. The BUP or BUPOH and opioid antagonist or opioid

means using Water or enZymes to cleave the connecting bond

agonist can be linked together via one or more cleavable

or group, thereby causing the codrug to be transformed into

linker moieties such as ester, thioester, carbonate, carbamate,
thiocarbamate, amide, thioamide, ureide, or any other suit
able chemical moieties providing that the chemistry is fea
sible. Preferably, the codrug comprises a carbonate ester link

the active parent drug molecules.
30

BRIEF DESCRIPTION OF THE DRAWINGS

age.
The linker moiety is preferably bioconvertible or biolabile.

FIG. 1 shoWs chemical structures of naltrexone (NTX, 1),

6-[3-naltrexol (NTXOL, 2), bupropion (BUP, 3), and
hydroxybupropion (BUPOH, 4).

35

FIG. 2 shoWs codrugs of hydroxybupropion With naltrex

one molecule of 6-[3-naltrexol and one molecule of BUPOH

one and naltrexol.

provides an unexpected increase of 6-[3-naltrexol maximum

FIGS. 3-6 shoW codrug synthesis steps.
FIG. 7 shoWs a hydrolytic pro?le of the carbonate codrug
(25) shoWing the hydrolysis into NTX and BUPOH in iso
tonic phosphate buffer pH 7.4 at 32° C.

40

?ux rate across the skin. Similar results Would be expected for
other codrugs set forth above.

The present invention also relates to methods for treating

conditions including pain, depression, narcotic dependence

FIG. 8. shoWs a chemical structure of the carbonate codrug,

and drug addiction. Subjects Who can bene?t from the meth

CB-NTXOL-BUPOH, consisting of 6-[3-naltrexol covalently
linked to a form of hydroxybupropion.

More preferably, the linker moiety is cleavable via hydrolysis
or enzymatic digestion.
As shoWn in the present examples, a codrug comprising

ods of the present invention include, for example, mammals,
45

such as humans, particularly humans Who are suffering from

FIG. 9. is a schematic diagram illustrating the hydrolytic
pathWay of CB-NTXOL-BUPOH to give 6-[3-naltrexol and

pain, depression, narcotic dependence, alcohol abuse, and/or

hydroxybupropion.

“Treatment” or “treating,” as used herein, refers to com
plete elimination as Well as to any clinically or quantitatively

alcoholism.

FIG. 10. shoWs a hydrolysis pro?le of the carbonate

codrug, CB-NTXOL-BUPOH, regenerating into 6-[3-naltr

50

measurable reduction in condition for Which the subject is
being treated. The methods of the present invention involve
delivering a therapeutically effective amount of the codrug. A
“therapeutically effective amount,” as used herein, refers to

55

treating the condition for Which the subject is being treated.

exol and hydroxybupropion in isotonic phosphate buffer pH
7.4 at 32° C. Solid lines represent predicted pro?les of the
drugs With time and data is represented as mean:s.d.
FIG. 11. is a representative permeation pro?le from satu
rated solutions of the carbonate codrug and 6-[3-naltrexol
(control) through human skin in vitro at 32° C. Data is rep

an amount, determined by one skilled in the art, su?icient for

The codrug can be delivered to a subject transdermally,

intravenously, orally, buccally, sublingually, by topical

resented as meaniSD (n:4 for CB-NTXOL-BUPOH treat

ment and n:3 for 6-[3-naltrexol treatment).
FIG. 12. shoWs the drug concentration of the carbonate
codrug and parent drugs in the skin after a 48 h diffusion study
folloWing application of drugs as saturated solutions in light

creams, subderrnally, as a sustained release depot, ophthalmi

cally, intranasally, aurally, by inhalation, rectally or vaginally.
60

molecules.
Transderrnal delivery is preferred. In a method for trans

mineral oil. Data is represented as meaniSD.

FIG. 13. is a hydrolysis pro?le of the carbonate codrug,

dermal delivery of the codrug, the steps comprise contacting

CB-NTXOL-BUPOH, in guinea pig plasma at 37° C.
FIG. 14. shoWs mean (:S.D.) plasma concentration pro

?les in guinea pigs after topical application of a gel formula
tion containing either CB-NTXOL-BUPOH (n:6) or 6-6

After delivery, the codrug is preferably biotransformed by
hydrolysis or enZymatic activity into at least tWo active drug

65

a section of human skin With the codrug and biotransforming

the codrug into tWo drugs by skin enZymes or by hydrolysis of
the codrug in the skin. A transdermal patch comprising a

US 8,653,271 B2
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suitable substrate and a layer of the codrug can be employed
to deliver the codrug to the skin.
The codrug is preferably administered as a pharmaceutical

patches suitable for use in the practice of the present invention
include those described in US. Pat. No. 5,223,262.
In another illustrative embodiment, the bandage, pad, or
other type of patch can be one Which is capable of controlling
the release of the codrug such that transdermal delivery of the
Codrug to the subject is substantially uniform and sustained

composition comprising pharmaceutically acceptable carri
ers, diluents, and/or excipients, Which are vehicles commonly
used to formulate pharmaceutical compositions for animal or
human administration. The carriers, diluents and/or excipi
ents are not intended to have biological activity themselves,

over a period of at least 12 hours, such as at least 24 hours, at

and are selected so as not to affect the biological activity of the

least 48 hours, and/or at least 7 days. Such a bandage, pad, or
other type of patch Which can be used in the practice of the

codrug and any other active agent(s). A pharmaceutically
acceptable carrier, diluent, and/or excipient as used herein

method of the present invention can take the form of an

includes both one and more than one such carrier, diluent,

and/or excipient. Examples include but are not limited to

includes the codrug is positioned on the subject’s skin under
conditions effective to transdermally deliver the codrug to the

distilled Water, saline, physiological phosphate-buffered
saline, Ringer’s solutions, dextrose solution, and Hank’s

subject’s skin.

occlusive body. In practice, the occlusive body Which

Other aspects and advantages of the present invention Will
be understood upon consideration of the folloWing illustrative

solution. Depending upon the manner of introduction, the
codrug may be formulated as, for example, a sterile injectable
formulation comprising aqueous solutions and/or suspen
sions containing the active materials in admixture With suit

able carriers, diluents, and/or excipients.
The concentration of codrug, the formulation (i.e., a for
mulation that is therapeutically effective to the subject to
Which it is administered) and the dose administered can be
readily determined by a person of ordinary skill in the art.
Typically, dosages used in vitro and in animal models, such as

examples. The examples are not to be construed in any Way as

limiting the scope of this invention.
20

Example 1
25

1.1 Introduction
Simultaneous treatment of alcohol abuse and tobacco

The codrug can be applied to the skin as a topical cream,
30

drinking (Mello, et al., Psychopharmacology 1987, 93 (1),
35

skin can be formulated as a topical cream, salve, gel, or

Watson, et al., Neuropharmacology 1999, 38, 587-595).
40

Wetting agents, preservatives, and suspending and dispersing
agents. In addition to the above, generally non-active compo
nents, topical formulations containing codrug can further
include other active materials, particularly, active materials
Which have been identi?ed as useful in the treatment of the

8-15). It also appears that alcohol drinking is increased in the
presence of nicotine; thus each addiction exacerbates the
other (KoZloWski, et al., J. Subst. Abuse Treat. 1993, 10 (2),

171-179; Mitchell, et al., Behav. Pharmacol. 1995, 6, 359
365; Glautier, et al., Behav. Pharmacol. 1996, 7, 144-154;
Smith, et al., Psychopharmacalogy 1999, 142, 408-412; and

ointment. The topical formulations can include inert diluents
and carriers as Well as other conventional excipients, such as

dependence is considered very desirable because of substan

tial evidence that smoking is increased signi?cantly during

is applied can optional be pre-treated With microneedles or
other permeability enhancers (see, e. g., Park et al., J. Control.

Release 104 (2005) 51-66 and PrausnitZ, Adv. Drug Deliv.
Rev. 56 (2004) 581-587).
Illustratively, a codrug composition that is applied to the

Synthesis and Hydrolytic Pro?le of Codrugs of
Naltrexone and 6-[3-naltrexol With

Hydroxybupropion

in the experiments provided in the present application, may
provide useful guidance in the amounts useful for in vivo
administration.

salve, ointment, gel, or other topical formulation; and/or by
using delivery devices such as bandages, occlusive bodies,
patches, and/or the like. The area of skin to Which the codrug

EXAMPLES

Opioid addicts also have a high prevalence of tobacco depen
dency and associated co-abuse problems, and Would bene?t
from a co-therapy approach. (Frosch, et al., Clin. Psychop

harmacology. 2000, 8 (1), 97-103).
Naltrexone (NTX, 1) (FIG. 1) is an opioid antagonist used
45

in the treatment of opioid addiction and alcohol dependence

condition for Which the subject is being treated, for example

(Volpicelli, et al., Arch Gen Psychiatry 1992, 49, 876-880).

drug and/or alcohol addiction, and Which can usefully be
delivered transdermally to the subject. For instance, such
other active materials can include acamprosate, disul?ram,

HoWever, NTX is a hepatotoxin that has been demonstrated to
have loW oral bioavailability, and adverse side effects, such as

topiramate, sertraline, rivastigmine, citalopram, and doxepin.

abdominal pain, constipation, nausea, and vomiting. Trans
50

The topical formulation canbe applied directly to the skin and
then optionally covered (e.g., With a bandage of gauZe) to
minimize the likelihood of its being disturbed. Alternatively,

With oral therapy, and improves compliance (RohsenoW, et
al., Alcoholism: Clinical and Experimental Research. 2000,
24(10), 1542-1549). Unfortunately, NTX itself does not have

the topical formulation can be coated on the surface of a

bandage, gauZe, etc., and the bandage, gauZe, etc. can then be

applied to the skin of the subject such that the topical forrnu
lation is in direct contact With the subj ect’s skin.
Alternatively, the codrug can be delivered transdermally to
the subject by formulating codrug into a bandage, pad, or
other type of patch Which can be applied to the subject’s skin.

dermal delivery is a desirable alternative route of admini stra

tion for NTX, since it helps reduce side effects associated

55

the necessary physicochemical properties that Would alloW a
therapeutic dose of the drug to cross the human skin barrier. In

recent years, improved transdermal drug delivery has been
achieved utiliZing more lipophilic prodrugs of NTX, Which
are more skin permeable than NTX (Stinchcomb, et al., J.
60

Pharm. Sci. 2002, 91, 2571-2578; Pillai, et al., Pharm. Res.

Illustratively, matrix-type transdermal patches, in Which

2004, 21, 1146-1152;Vaddi, etal.,Pharm. Res. 2005, 22 (5),

the codrug is disposed in an adhesive matrix, can be

758-765; and Valiveti, et al., J. Contr Rel. 2005, 102(2),

employed. The matrix-type transdermal patch can further

509-520). This same approach can be utiliZed in the design of

include other active materials for transdermal delivery to the
subject With the codrug. Suitable adhesives for use in such

synergistic codrugs of either NTX or [3-naltrexol (NTXOL, 2)
(FIG. 1), the active metabolite of NTX (McCaul, et al., Alca
hol: Clin. Exp. Res. 2000, 24(9), 1385-1391; Rukstalis, et al.,
Clin. Exp. Res. 2000, 24(10), 1593-1596; Porter, et al., British

matrix-type transdermal patches include polyisobutylenes,
acrylates, silicone, and combinations thereof. Still other
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Journal ofClinicalPharmacology 2000, 50(5), 465-471; and
Wang, et al., Journal ofNeurochemisZry 2001, 77(6), 1590
1 600).
Bupropion (BUP, 3) (FIG. 1) is an antidepressant medica

N-acylation reaction conditions (FIG. 3) utiliZing bupropion
and phos gene under a variety of conditions and solvents in the

presence of triethylamine, folloWed by addition of NTX,
afforded the stable cyclic product 9 and unreacted NTX.

tion and a therapeutic agent currently used in the treatment of
nicotine dependence as a smoking cessation agent. Hydroxy

When BUP Was reacted With phosgene in the absence of

NTX, 9 Was formed in good yield, rather than the expected
chlorocarbonyl intermediate 5 (FIG. 3). This result indicates
that the chlorocarbonyl intermediate 7 is not stable enough to

bupropion (BUPOH, 4) (FIG. 1), is the major metabolite of
BUP, and is believed to contribute to its antidepressant activ
ity, as Well as the smoking-cessation properties of BUP (Coo

be isolated, and its half-life appears to be too short for the

per, et al., Neuropsychopharmacology 1994 (1994), 11 (2),
133-141; Ascher, et al., Journal of Clinical Psychiatry 1995,
56 (9), 395-401; Sanchez and Hyttel, J. Cell. Mol. Neurobiol.
1999, 19 (4), 467-489; Slemmer, et al., JPET 2000, 295(1),

reaction With NTX to occur. The formation of 9 can be

explained by 5 existing in an equilibrium mixture With its enol
tautomer 6, Which then undergoes rapid intramolecular
O-acylation to form 9.

321-327). It is likely that BUP may be acting as a nicotinic

Hussain (Hussain, et al., J. Pharm. Sci. 1987, 76, 356-358)
and Nelson (Olsen, et al., J. Med. Chem. 1990, 33, 737-741)

receptor antagonist, and that this property is responsible for
the smoking cessation properties of the drug (Slemmer, et al.,

have reported the synthesis of a number of 3-O- and 6-O-ester
analogs of NTX and NTXOL. These methodologies do not

2000). BUP and BUPOH are drug molecules that are consid

ered ideally suitable, from both a chemical and pharmaco
logical perspective, for covalent linkage to NTX and NT'XOL
to afford clinically useful codrug entities for the treatment of
both alcohol abuse and tobacco dependence. Both NTX and

20

require protection of the C-14 hydroxyl group, due to its
unreactivity, Which results from the signi?cant steric hin
drance around this functional group. Under the reaction con

ditions described by Hussain, O-acylation of NTX in the

BUP are administered in therapeutic doses that are similar, on
a molar ratio basis, indicating that a 1:1 ratio of these tWo

presence of base is regiospeci?c for the more reactive C-3

drugs in a codrug entity Would have therapeutic potential.

phenolic group (as the phenolate anion). Similarly, O-acyla

The present invention includes a series of novel NTX and
NTXOL codrugs covalently linked to either BUP or BUPOH
via an enZymatically cleavable linker moiety. These mol
ecules Were designed to determine if such codrugs could
increase the delivery rate of NTX and NTXOL across human
skin When covalently linked to either BUP or BUPOH. If

25
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successful, this approach could improve pharmacotherapy for
both alcohol abuse and tobacco dependency by providing a

single, clinically effective, transdermal codrug dosage form
to treat both co-dependent conditions.

Thus, the main therapeutic goal of this approach Was to

35

design a codrug that could afford a transdermal ?ux from 2.8

toz12-90 nmol/cm2/hr across the skin, folloWed by rapid
metabolism of the codrug to achieve therapeutically effective
levels of the tWo parent drugs in the body. The conversion of
the highly crystalline and high melting NTX to a covalently

40

linked codrug With BUP or BUPOH should afford a loWer

melting and more lipid soluble molecule. Drugs With high
melting points often have corresponding loW oil solubilities
(Stinchcomb, et al., Pharm. Res. 1995, 2, 1526-1529). Trans
dermal delivery of a drug is in part related to it’s lipid solu

tion of NTXOL in the presence of base is regiospeci?c for the
3-OH group (De Costa, et al., J. Med. Chem. 1992, 35, 2826
2535). Thus, no prior protection of either the 14- or 6-[3OH
group in either NTX or NTXOL is required for regiospeci?c
3-O-acetylation of these molecules. With this in mind, in an
alternative strategy, the synthesis of codrugs 7 and 8 via
intermediate 10 (FIG. 4), Which Was formed from the reaction
of NTX and phosgene in the presence of triethylamine, Was
attempted. Under these conditions, the reaction of NTX With

phosgene afforded exclusively the dimeric 3-O, 3'-O carbon
ate ester of NTX (1 1, FIG. 4) rather than the expected NTX
3-O-chlorocarbonyl intermediate 10. (Hammell, et al., Jour
nal of Controlled Release 2004, 97(2), 283-290). Also, When
this reaction Was carried out in the presence of BUP, both 11
and 9 Were formed, and no codrug could be detected in the
reaction mixture. The use of a variety of different reactions
conditions in these reactions failed to yield the desired inter

mediate 10, affording only 11 in good yield. Similarly, When
45

NTXOL Was utiliZed in place of NTX, reaction With phos
gene resulted in the formation of the corresponding dimeric

bility, as this establishes the limit of attainable driving force
across the skin (Flynn, In Principles of Roule-lo-Roule

3-O, 3'-O carbonate ester ofNTXOL, 13 (FIG. 4).
Efforts to synthesiZe codrugs 14-17 (FIG. 2) of BUPOH

Exlrapolalionfor RiskAssessmenZ. 1990, Gerrity, T. R.; and

With NTX or NTXOL Were also explored. The hemiketal

Henry, C, J. (eds.), Elsevier, N.Y., 93-127). Increased lipo
philicity of a drug causes an increase in its skin permeability
up to a maximum. Thus, the codrug design Was utiliZed to

50

push the lipophilicity envelope to its optimal value, in order to
take advantage of maximal transdermal ?ux, but also to avoid
problems of viable tissue controlled diffusion. (Stinchcomb,
et al., Pharm. Res. 1995, 2, 1526-1529).
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1.2 Results and Discussion

Chemistry
A codrug is formed by chemical conjugation of tWo or
more drugs via a suitably designed labile linker unit. The
drugs are usually linked via linker moieties, such as ester,
carbonate, amide, carbamate, etc., Which are then cleaved
enZymatically to regenerate the active drug molecules at a

60

required site in the body.
In efforts to synthesiZe the carbonate codrugs 7 & 8 (FIG.
3), Which are codrugs of BUP covalently linked to either NTX
or NTXOL, initial coupling of the tWo molecules utiliZing
phosgene as the linker precursor Was attempted. Firstly,

form of BUPOH, 4, exists in equilibrium With its uncycliZed
form, 18 (FIG. 5). Thus, if the hemiketal form of BUPOH, 4,
is reacted With phosgene, then either the chlorocarbamate
intermediate 19 (FIG. 5), the chlorocarbonate intermediate 20
(FIG. 5), or both, could be formed, either of Which if coupled
With NTX or NTXOL Would afford codrugs 14-17 (FIG. 2).
Also, there is a possibility that the formation of 19 might be
folloWed by ring opening, leading to the formation of 21
(FIG. 5). On the other hand, if the ring-open form of BUPOH,
18, reacts With phosgene, the chlorocarbamate intermediate,
21, Would be expected to be formed. If 21 is stable enough to
couple to NTX or NTXOL, it may undergo subsequent
cycliZation to the hemiketal form, resulting in the formation
of codrugs 14-17. Also, BUPOH may be initially N-chloro
carbonylated to afford 21 , Which, like the corresponding BUP
analog, 6, can exist in equilibrium With its enol tautomer, 22
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(FIG. 5), folloWed by rapid intramolecular O-acylation to 23
(FIG. 5). When equimolar amounts of BUPOH and phosgene
Were reacted under basic conditions, the phosgene-BUPOH

US 8,653,271 B2
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intermediate 23 (FIG. 5) Was formed as the major product in
the reaction. Compound 23 could be isolated, puri?ed and

NTX or NT'XOL folloWed by hydrolytic cleavage of the

fully characterized.
These results clearly indicate that the ring opened and

BUPOH.

resulting cyclic BUPOH intermediate 23, to generate

The Physicochemical Properties of the Codrugs.
A more qualitative basis for the design of codrugs to

cycliZed (hemiketal) forms of BUPOH are in dynamic equi
librium under the conditions of the initial acylation reaction

enhance transdermal delivery of NTX or NTXOL is to

With phosgene (FIG. 5), although the possibility that 22 might

improve the physicochemical properties essential for
increased permeation through skin. Some of the physico

be formed by ring opening of 19, if it is formed, cannot be
excluded. Unlike the corresponding BUP analog, 9, interrne

chemical properties of codrugs 25 and 26 Were measured and
compared to those for NTX or NTXOL, and these are shoWn
in Table 1.

diate 23 has a terminal hydroxyl group that can be utiliZed for
linking With NTX or NTXOL via a carbonate moiety. Fur

thermore, the cyclic carbonate analog of BUPOH, 23, is
expected to be enZymatically cleaved to BUPOH in vivo.

TABLE 1

Thus, this modi?ed BUPOH entity Was considered to be a
valid substitute for BUPOH in BUPOH-NTX or BUPOH

Physicochernical properties of NTX, NTXOL,

NTXOL codrug molecules. Also, When BUPOH Was reacted
With excess phosgene under basic conditions, the intermedi
ate 24 (FIG. 5) Was the major product in the reaction. Inter
mediate 24 could be isolated and fully characteriZed, and
afforded the modi?ed codrug 25 (FIG. 5) on treatment With
NTX in dichloromethane.
In a similar manner, the desired NTXOL-BUPOH codrug
26 (FIG. 5) Was obtained When compound 24 Was reacted
With NTXOL in dichloromethane in the presence of triethy

and the carbonate codrugs 25 and 26.

20

MP (0 C.)

1
2
4
25
26

341.40
343.42
255.74
649.13
651.15

175.7 1 1.20
187.76 1 2.62
124.40 1 1.60
137.00 1 1.41
159.501212

clog PI Half-life, tl/2 (hrs)*
0.36
0.83
2.87
3.23
3.71

stable
stable
stable
36.68 1 2.88
28.881282

25

The melting points of the codrugs Were measured because.
This physical property can be easily related to the drug solu

bility properties. (Stinchcomb, et al., Pharm. Res. 1995, 2,
1526-1529; Jain, et al., J. Pharrn. Sci. 2001, 90, 234-252). As

lation reaction With phosgene (FIG. 5).
30

shoWn in Table 1, the calculated clog P values Were found to
be higher for the codrugs compared to those for the corre

sponding parent drugs. The clog P value provides a Way of
estimating the lipophilicity of a drug, and the higher the clog
P value the more lipophilic the drug. Increased lipophilicity

capable of reverting back to the parent drugs in the body by
enZymatic or chemical action. The reconversion rate must be

MW

IDerived from Daylight ® Software
*St'udied in isotonic phosphate buffer, pH 7.4 at 32° C.

lamine. These results again indicate that the ring opened and
cycliZed (hemiketal) forms of BUPOH are in dynamic equi
librium under the conditions of the initial N-chlorocarbony
Hydrolysis Studies on Codrugs 25 and 26.
Any drug that is to be formulated into a dosage form must
exhibit stability in the medium that it is formulated in. On the
other hand, the BUPOH-NTX/NTXOL codrugs must be

Compound

35

of a transdermal drug causes an increase in skin permeability

adequate in order to deliver the active drugs effectively. In this

and is primarily attributed to an increase in the partitioning of

respect, neither a codrug that degrades in its vehicle nor one
that never reverts to the parent drugs has any therapeutic

the drug into the skin. Another important physicochemical
property necessary for enhancement of transdermal delivery
is rapid bioconversion of the codrug to the corresponding
parent drugs. Rapid bioconversion rates of codrugs are rep
resented by short half-lives in isotonic phosphate buffer (pH

value. A codrug that does not have enough chemical stability
to Withstand the rigors of transport across the stratum cor
neum is equally Worthless.

Although it is considered that codrugs 25 and 26 are likely
to be cleaved enZymatically in vivo to generate BUPOH and
NTX and BUPOH and NTXOL, respectively, initial studies
on the hydrolysis of these codrugs in buffer at physiological

40

7.4/32o C.), and these values can be signi?cantly increased in
vivo, because in addition to hydrolysis, the codrugs are also
susceptible to enZymatic action by esterases. In addition to
45

regeneration of the active parent drugs, rapid bioconversion

pH should provide good evidence that the parent drugs Will be

of the codrugs in the skin causes an enhancement of the

e?iciently formed. To determine Whether codrugs 25 and 26
could be hydrolyZed to the parent drugs, hydrolysis studies
Were carried out at physiological (pH 7.4) using isotonic
phosphate buffer. Skin has been shoWn to be a metabolically
active organ for NTX carbonate prodrugs. (Pillai, et al.,

concentration gradient across skin, and consequently leads to

50

have been synthesiZed, and the kinetics of their hydrolysis
also studied. The physicochemical properties of these 25 and
26 codrugs indicate that both codrugs have the capability to

Pharm. Res. 2004, 21, 1146-1152). Thus, these carbonate
codrug molecules should also be susceptible to hydrolytic
cleavage, and We anticipated the hydrolytic conversion to
proceed as illustrated in FIG. 6.
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parent drugs. Thus, the tWo codrugs 25 and 26 are predicted to
be cleaved enZymatically in vivo to generate BUPOH and

NTX and BUPOH, and the disappearance of the carbonate
60

kl and k3 Were calculated to be 0.0179 hr-1 and 0.0483 M“,
respectively, for generation of NTX and BUPOH.
Similarly, hydrolytic studies With codrug 26 Were also
carried out, and the corresponding rate constants k1, and k2
Were calculated to be 0.0240:0.0007 hr“1 and 00139100006

M“, respectively. Thus, both codrugs 25 and 26 appear to
hydrolyZe rapidly at the carbonate linker moiety to afford

permeate the skin at a higher rate When compared to either
NTX or NTXOL. Both codrugs Were hydrolyZed in isotonic

phosphate buffer (pH 74/ 32° C.) and e?iciently released the

The chemical stability of the codrug 25 in isotonic phos
phate buffer at pH 7.4 Was studied over 4 days. Concentration
versus time curves for the appearance of the parent drugs
codrug 25 are shoWn in FIG. 7. The ?rst-order rate constants

an increased potential of the drug to cross the skin barrier.
1.3 Conclusions
TWo novel codrugs of NTX and NTXOL With BUPOH

NTX, and BUPOH and NTXOL, respectively, representing
potential candidates for transdermal delivery of these drug
entities for the treatment of both alcohol abuse and tobacco

dependency.
1.4 Experimental Section

Chemistry
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All purchased solvents and reagents Were used Without

further puri?cation. Phosgene Was purchased from Fluka
Chemie AS. (Note!!! Care must be exercised in the handling

